Advances in circulating microRNAs as diagnostic and prognostic markers for ovarian cancer

Cancer Biology and Medicine

Volumn 10, Issue 3, 2013, Pages 123-130

  Zheng, Hong ^a   Liu, Jia Yu ^a   Song, Feng Ju ^a   Chen, Ke Xin ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Biological markers; Early diagnosis; MicroRNAs; Ovarian neoplasms

Indexed keywords

MICRORNA;

BLOOD SAMPLING; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL PRACTICE; EARLY DIAGNOSIS; GENE EXPRESSION; GENE REPRESSION; HUMAN; OVARY CANCER; REVIEW;

EID: 84891332961     PISSN: 20953941     EISSN: None     Source Type: Journal    
DOI: 10.7497/j.issn.2095-3941.2013.03.001     Document Type: Review

References (47)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11-30.
2. Cannistra S A. Cancer of the ovary. N Engl J Med 2004;351:2519-2529.
3. The National Cancer Research and Control Office, National Cancer Registry, The bureau of disease control and prevention of the Ministry of Health. Annual Cancer Registration Report in China, 2004. Beijing: Beijing Union Medical University Press 2008;141:333.
4. Bartel D P. MicroRNAs: target recognition and regulatory functions. Cell 2009;136:215-233.
5. Lee R C, Feinbaum R L, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993;75:843-854.
6. Mitchell P S, Parkin R K, Kroh E M, Fritz B R, Wyman S K, Pogosova-Agadjanyan EL, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 2008;105:10513-10518.
7. Häusler S F, Keller A, Chandran P A, Ziegler K, Zipp K, Heuer S, et al. Whole blood-derived microRNAs profiles as potential new tools for ovarian cancer screening. Br J Cancer 2010;103:693-700.
8. Taylor D D, Gercel-Taylor C. MicroRNA signatures of tumorderived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol Oncol 2008;110:13-21.
9. Chim S S, Shing T K, Hung E C, Leung T Y, Leung T Y, Lau T K, et al. Detection and characterization of placental microRNAs in maternal plasma. Clin Chem 2008;54:482-490.
10. Lawrie C H, Gal S, Dunlop H M, Pushkaran B, Liggins A P, Pulford K, et al. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol 2008;141:672-675.
11. Hafner M, Landgraf P, Ludwig J, Rice A, Ojo T, Lin C, et al. Identification of microRNAs and other small regulatory RNAs using cDNA library sequencing. Methods 2008;44:3-12.
12. Fu H, Tie Y, Xu C, Zhang Z, Zhu J, Shi Y, et al. Identification of human fetal liver MicroRNAs by a novel method. FEBS Lett 2005;579:3849-3854.
13. Pall G S, Hamilton A J. Improved northern blot method for enhanced detection of small RNA. Nat Protoc 2008;3:1077-1084.
14. Liu C G, Calin G A, Meloon B, Gamliel N, Sevignani C, Ferracin M, et al. An oligonucleotide microchip for genome-wide microRNA profiling in human and mouse tis-sues. Proc Natl Acad Sci USA 2004;101:9740-9744.
15. Chen C, Ridzon D A, Broomer A J, Zhou Z, Lee D H, Nguyen J T, et al. Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res 2005;33:e179.
16. Fu H J, Zhu J, Yang M, Zhang Z Y, Tie Y, Jiang H, et al. A novel method to monitor the expression of microRNAs. Mol Biotechnol 2006;32:197-204.
17. Driskell J D, Seto A G, Jones L P, Jokela S, Dluhy R A, Zhao Y P, et al. Rapid microRNA (miRNA) detection and classification via surface-enhanced Raman spectroscopy (SERS). Biosens Bioelectron 2008;24:923-928.
18. Kato Y. An efficient fluorescent method for selective detection of mature miRNA species. Nucleic Acids Symp Ser (Oxf) 2008;15:71-72.
19. Rupp A K, Rupp C, Keller S, Brase J C, Brase J C, Ehehalt R, et al. Loss of EpCAM expression in breast cancer derived serum exosomes: Role of proteolytic cleavage. Gynecol Oncol 2011;122:437-446.
20. Raposo G, Tenza D, Mecheri S, Peronet R, Bonnerot C, Desaymard C. Accumulation of major histocompatibility complex class II molecules in mast cell secretory granules and their release upon degranulation. Mol Biol Cell 1997;8:2631-2645.
21. Heijnen H F, Schiel A E, Fijnheer R, Geuze H J, Sixma J J. Activation platelets release two types of membrane vesicles: microvesicles by surface shedding and exosomes derived from exocytosis of multivesicular bodies and alpha granules. Blood 1999;94:3791-3799.
22. Taylor D D, Black P H. Shedding of plasma membrane fragments: Neoplastic and developmental importance. Dev Biol (N Y 1985) 1986;3:33-57.
23. Taylor D D, Bohler H C, Gercel-Taylor C. Pregnancy-linked suppression of TcR signaling pathways by a circulating factor absent in recurrent spontaneous pregnancy loss. Mol Immunol 2006;43:1872-1880.
24. Iorio M V, Visone R, Di Leva G, Donati V, Petrocca F, Casalini P, et al. MicroRNA signatures in human ovarian cancer. Cancer Res 2007;67:8699-8707.
25. Resnick K E, Alder H, Hagan J P, Richardson D L, Croce C M, Cohn D E. The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. Gynecol Oncol 2009;112:55-59.
26. Chung Y W, Bae H S, Song J Y, Lee J K, Lee N W, Kim T, et al. Detection of MicroRNA as Novel Biomarkers of Epithelial Ovarian Cancer from the Serum of Ovarian Cancer Patient. Int J Gynecol Cancer 2013;23:673-679.
27. Curiel T J, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004;10:942-949.
28. Marigo I, Dolcetti L, Serafini P, Zanovello P, Bronte V. Tumorinduced tolerance and immune suppression by myeloid derived suppressor cells. Immunol Rev 2008;222:162-179.
29. Tu S, Bhagat G, Cui G, Takaishi S, Kurt-Jones E A, Rickman B, et al. Overexpression of interleukin-1beta induces gastric inflammation and cancer and mobilizes myeloid-derived suppressor cells in mice. Cancer Cell 2008;14:408-419.
30. Kaplan R N, Riba R D, Zacharoulis S, Bramley A H, Vincent L, Costa C, et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 2005;438:820-827.
31. Suryawanshi S, Vlad A M, Lin H M, Mantia-Smaldone G, Laskey R, Lee M, et al. Plasma microRNAs as novel biomarkers for endometriosis and endometriosis-associated ovarian cancer. Clin Cancer Res 2013;19:1213-1224.
32. Tinelli A, Vergara D, Martignago R, Leo G, Pisanò M, Malvasi A. An outlook on ovarian cancer and borderline ovarian tumors: focus on genomic and proteomic findings. Curr Genomics 2009;10:240-249.
33. van Jaarsveld M T, Helleman J, Berns E M, Wiemer E A. MicroRNAs in ovarian cancer biology and therapy resistance. Int J Biochem Cell Biol 2010;42:1282-1290.
34. Dahiya N, Sherman-Baust C A, Wang T L, Davidson B, Shih IeM, Zhang Y, et al. MicroRNA expression and identification of putative miRNA targets in ovarian cancer. PLoS One 2008;3:e2436.
35. Zhang L, Volinia S, Bonome T, Calin G A, Greshock J, Yang N, et al. Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer. Proc Natl Acad Sci USA 2008;105:7004-7009.
36. Zaman M S, Maher D M, Khan S, Jaggi M, Chauhan S C. Current status and implications of microRNAs in ovarian cancer diagnosis and therapy. J Ovarian Res 2012;5:44.
37. Büssing I, Slack F J, Grosshans H. Let-7 microRNAs in development, stem cells and cancer. Trends Mol Med 2008;14:400-409.
38. Kan C W, Hahn M A, Gard G B, Maidens J, Huh J Y, Marsh D J, et al. Elevated levels of circulating microRNA-200 family members correlate with serous epithelial ovarian cancer. BMC Cancer 2012;12:627.
39. Shih Ie M, Kurman R J. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol 2004;164:1511-1518.
40. Garzon R, Marcucci G, Croce C M. Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov 2010;9:775-789.
41. Yu F, Yao H, Zhu P, Zhang X, Zhang X, Pan Q, et al. let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell 2007;131:1109-1123.
42. Johnson S M, Grosshans H, Shingara J, Byrom M, Jarvis R, Cheng A, et al. RAS is regulated by the let-7 microRNA family. Cell 2005;120:635-647.
43. Yang H, Kong W, He L, Zhao J J, O'Donnell J D, Wang J, et al. MicroRNA expression profiling in human ovarian cancer: miB-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res 2008;68:425-433.
44. Zhu H, Wu H, Liu X, Evans B R, Medina D J, Liu C G, et al. Role of microRNA miR-27a and miR-451 in the regulation of MDR1/P-glycepmtein expression in human cancer cells. Biochem Pharmacol 2008;76:582-588.
45. Li Z, Hu S, Wang J, Cai J, Xiao L, Yu L, et al. MiR-27a modulates MDRl/P-glycoprotein expression by targeting HIPK2 in human ovarian cancer cells. Gynecol Oncol 2010;119:125-130.
46. Marfella R, Di Filippo C, Potenza N, Sardu C, Rizzo M R, Siniscalchi M, et al. Circulating microRNA changes in heart failure patients treated with cardiac resynchronization therapy: responders vs. nonresponders. Eur J Heart Fail 2013;15:1277-1288.
47. Wang J F, Yu M L, Yu G, Bian J J, Deng X M, Wan X J, et al. Serum miR-146a and miR-223 as potential new biomarkers for sepsis. Biochem Biophys Res Commun 2010;394:184-188.